Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Malignant hypercalcemia--a hospital survey.

C P Blomqvist

    Acta Medica Scandinavica
    |January 1, 1986
    PubMed
    Summary

    Malignant hypercalcemia affects 1.5% of cancer patients, often linked to advanced disease and bone metastases. Treatment can lower serum calcium and improve prognosis, with a 31% one-year survival rate.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Comparative genomic hybridization of postirradiation sarcomas.

    Cancer·2001
    Same author

    The adhesion molecule CD44v6 is associated with a high risk for local recurrence in adult soft tissue sarcomas.

    British journal of cancer·2001
    Same author

    Five-year results in Ewing's sarcoma. The Scandinavian Sarcoma Group experience with the SSG IX protocol.

    European journal of cancer (Oxford, England : 1990)·2000
    Same author

    Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer.

    British journal of cancer·2000
    Same author

    A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients.

    British journal of cancer·1999
    Same author

    Expression of cyclin A in soft tissue sarcomas correlates with tumor aggressiveness.

    Cancer research·1999

    Area of Science:

    • Oncology
    • Endocrinology
    • Medical Research

    Background:

    • Hypercalcemia is a common complication in cancer patients.
    • Understanding the prevalence and causes of malignant hypercalcemia is crucial for patient management.

    Purpose of the Study:

    • To determine the frequency of hypercalcemia in patients with malignant disease.
    • To identify the primary causes and associated factors of malignant hypercalcemia.
    • To evaluate the impact of treatment on serum calcium levels and patient prognosis.

    Main Methods:

    • Retrospective analysis of patients attending a large oncological center.
    • Assessment of hypercalcemia prevalence and etiological factors.
    • Correlation of hypercalcemia with cancer type, disease stage, and bone metastases.
    • Evaluation of treatment outcomes and survival rates.

    Main Results:

    • Hypercalcemia occurred in 1.5% of patients with malignant disease.
    • Malignant etiology was confirmed in 80% of cases.
    • Hypercalcemia was most common in multiple myeloma, renal carcinoma, squamous cell carcinomas, and breast cancer.
    • Advanced, metastasized disease, particularly with bone involvement (80% in solid tumors), was frequently observed.
    • Treatment effectively reduced serum calcium levels.
    • One-year actuarial survival for patients with malignant hypercalcemia was 31%.

    Conclusions:

    • Malignant hypercalcemia is a significant complication in cancer patients, predominantly linked to advanced disease and bone metastases.
    • Active treatment of hypercalcemia is associated with improved prognosis and survival.
    • Further research into the mechanisms and optimal management of malignant hypercalcemia is warranted.

    Related Experiment Videos